The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer

• Principais autores: Dariusz Rozkiewicz (Autor), Justyna Magdalena Hermanowicz (Autor), Anna Tankiewicz-Kwedlo (Autor), Beata Sieklucka (Autor), Krystyna Pawlak (Autor), Robert Czarnomysy (Autor), Krzysztof Bielawski (Autor), Arkadiusz Surazynski (Autor), Joanna Kalafut (Autor), Alicja Przybyszewska (Autor), Mariusz Koda (Autor), Katarzyna Jakubowska (Autor), Adolfo Rivero-Muller (Autor), Dariusz Pawlak (Autor)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2020-01-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Recombinant human erythropoietin (Epo) is an effective and convenient treatment for cancer-related anaemia. In our study for the first time, we evaluated the effect of simultaneous use of Epo and Bruton's tyrosine kinase (BTK) inhibitor LFM-A13 on the viability and tumour development of breast...